



Shea Cancer Program

Annual Report – 2013

Table of Contents

Cancer Program Activities	3
Physician Cancer Committee Members	4
Non-Physician Cancer Committee Members	4
Cancer Conferences	5
Top Ten Analytic Cancer Incidence by Gender - Male	5
Top Ten Analytic Cancer Incidence by Gender - Female	5
Analytic Incidence by Age Group and Gender	5
Standard of Care Quality Measures of Commission on Cancer	6
System-wide 2012 Primary Site Table	8
Shea 2012 Primary Site Table	9
Osborn 2012 Primary Site Table	11
Thompson Peak 2012 Primary Site Table	13

Community Outreach at Scottsdale Healthcare is very active. In 2013, cancer programs alone numbered over 579 with 42,698 participants plus exposure to an additional 150,000 people at three large events (Parada Del Sol and Komen) for a total of 177,610 people.

Community Outreach Support Group Meetings Included:

- BRCATEERS (BRCA Positive Support Group)
- Cancer Support and Education Forum
- Network of Strength Breast Cancer Support Group
- Bosom Buddies Support Group
- Facing Forward Women's Support Group
- AZ Myeloma Network Caregiver Education Support Program
- Celebration For Life – Transplant Survivors
- Psychosocial Aspect of Cancer Survivorship Support Group
- LLS Society Peer Support Training

Community Outreach Events:

- Light The Night Event
- Central Phoenix Women
- Parada Del Sol Parade
- Parada Del Sol Rodeo
- Cheyenne Traditional School PTO Golf Tournament Cancer Risk and Prevention Education Resources
- Tina's Treasures Sweet Spring Annual Event
- Nutrition / Colon Event

- Lymphedema New Patient Orientation
- AZ Women's Expo
- Bras For The Cause Event with Susan G. Komen at PV Mall
- Ovarian Walk
- AZ Bike Week
- Hayden Cross Health Expo
- AZ Foothills Expo
- Relay For Life Fountain Hills
- Women of Scottsdale
- West Valley Women
- Central Phoenix Women
- Holiday Celebration of Lights
- Phoenix Symphony VGPC Music is Healing Program
- StepNOOut Pancreatic Cancer Walk
- Annual National Cancer Survivorship Day

Community Outreach Cancer Screenings Included:

- LPGA Golf Tournament Risk and Prevention Skin Screenings
- VI at Silverstone Senior Health Day UV Skin Screenings, Breast Health Education Resource
- Annual Skin Screening
- Annual Prostate Screening
- Thompson Peak Ladies Night Out UV Skin Screening and Nutrition Program

Community Outreach Educational Programs Included:

- Lymphedema Education Program
- Lymphedema New Patient Orientation
- Women's Health Program
- Below The Belt Prostate Educational Event
- AZ Myeloma Conference
- Cancer Support and Education Forum
- Ask The Expert Cancer Prevention
- Ladies Night Breast Health Education
- Dillard's Breast Health Event
- Undy 5000 Colon Cancer Awareness Event
- Women's Marathon Breast Health Event
- Playing for Time
- Power of Pink Mall Event
- Be The Match Drive
- Women's Wellness Program
- Breast Cancer Lunch n Learn
- Loving, Learning and Living with Cancer
- My Hope Bag Cancer Conference

**Community Outreach
Complementary Therapy Programs
Included:**

- Yoga
- Tai Chi
- QI Gong
- Healing Art
- Meditation
- Holistic Assessment
- Reiki and Relaxation
- ASU Presentation for Women's Week
- Library Presentation
- Cardiac Rehab Group Presentation

Physician Committee Members	2013
Jeffrey Isaacs	Medical Oncology
Patrick Donovan	Medical Oncology
Jeffrey Van Lier Ribbink	General Surgery
Farley Yang	Radiation Oncology
James Newell	Pathology
Ron Korn	Radiology
Ramesh Ramanathan	Medical Oncology / Research

**Community Outreach Nutrition
Programs Included:**

- Eating For Life – Eat Real
- Nutrition Talk for Wellness Community
- ASU Employee Wellness Sky Song
- Scottsdale Leadership
- Men's Group Nutrition
- Waldenstrom's Support Group Nutrition
- Osteoporosis Support Group Nutrition
- Cooking Intensive
- National Lymphoma Research Conference

Non-Physician Members	2013
Dean Thomas	VP
Lindsay Thomas	Director- Oncology Service Line
Colleen McKeague	Medical Staff
Donald Day	Oncology Manager
Carol Guarnieri	Oncology Nurse Specialist
Cary Armstrong	Genetic Counseling
Suzanne Hyde	Oncology Social Worker

Nancy McCutcheon	Community Outreach Manager
Faith Henson	Mgr Surgical Oncology
Melanie O'Hara	Care Coordinator
Marlene Miller	Care Coordinator
Terri Taylor	Nutrition Services
Terry Thomas	Cancer Registry
Patrice Welsh-Benjamin	Oncology Nurse Clinician

2012 Shea Cancer Conferences

There were 89 tumor boards held at Shea in 2012 (42 general, 22 breast, 10 thoracic, 10 endocrine and 4 sarcoma). There were 282 cases presented (126 general, 80 breast, 28 thoracic, 24 endocrine and 24 sarcoma). Of them 274 (97.2%) were prospective presentations.

Physician attendance at Shea tumor boards numbered 1045 and averaged 14.3 at general, 9.7 at breast, 7.3 at thoracic, 11.4 at endocrine and 11.3 at sarcoma.

Non-physician attendance at Shea tumor boards numbered 588 and averaged 7.5 at general, 9.3 at breast, 2.6 at thoracic, 2.3 at endocrine and 4.5 at sarcoma.

There were an additional 42 general tumor boards held at Osborn in 2012 with 444 physicians attending for an average of 10.6 per meeting and 298 non-physicians attending for an average of 7.1 per meeting.

Ten Most Common Analytic Cancers Per Gender (2012 data)

Male Top Ten Sites	Incidence	Percentage Of Total Male Cases (n=859)
Prostate	283	33%
Bladder	104	12%
Lung	59	7%
Kidney	59	7%
Colorectal	55	6%
Leukemia	52	6%
Melanoma	43	5%
Thyroid	36	4%
Lymphoma	30	4%
Pancreas	25	3%
Female Top Ten Sites	Incidence	Percentage Of Total Female Cases (n=859)
Breast	366	42%
Thyroid	125	14%
Lung	53	6%
Melanoma	38	4%
Colorectal	34	4%
Leukemia	31	4%
Bladder	31	4%
Ureter	29	3%
Pancreas	25	3%
Kidney	25	3%

Note: Cervical carcinoma in situ, squamous or basal cell carcinomas of skin and intraepithelial neoplasias were excluded.

Among men, prostate cancer was the most prevalent. Prostate cancer accounted for 32.5 of every 100 cancers accessioned at Shea among men.

Among women, breast cancer was the most prevalent. Breast cancer

accounted for 41.8 of every 100 cancers accessioned at Shea among women.

Patients in their sixties accounted for 29% of all accessions in 2012. Patients in their fifties and in their seventies accounted for 21% and 22%, respectively. Collectively, patients of age 50 – 79 accounted for 72% of all 2012 cases.

**Analytic Cases
Age by Gender (2012 data)**

Age	Male	Female	Total
1-9	1	1	2
10-19	5	4	9
20-29	16	24	40
30-39	19	59	78
40-49	51	114	165
50-59	173	193	366
60-69	287	213	500
70-79	202	169	371
80-89	93	77	170
90-99	12	14	26
≥ 100	0	0	0
Total	859	868	1727

SCOTTSDALE HEALTHCARE SHEA
Cancer Program Practice Profile Reports Summary for Breast, Colon and Rectal Cancers

Performance rates from the Commission on Cancer National Cancer Data Base for 2010 diagnoses comparison among SHC Shea, SHC Shea's upper limit of the 95% Confidence Interval, all Arizona accredited programs, and all CoC accredited programs.

Breast Cancer Measures

Measure	SHC Shea	SHC Shea 95% C.I.	AZ Accredited programs	CoC Accredited Programs
Radiation therapy is administered within 1 year of diagnosis for women under age 70 receiving breast conserving surgery for breast cancer (Std 90%)	86.7%	94.4%	74.7%	91.0%
Combination chemotherapy is considered or administered within 4 months of diagnosis for women under 70 with AJCC T1c N0 M0, or Stage II or III ERA and PRA negative breast cancer (Std 90%)	87.5%	103.7%	73.7%	91.8%
Tamoxifen or third generation aromatase inhibitor is considered or administered within 1 year of diagnosis for women with AJCC T1c N0 M0, or Stage II or III ERA and/or PRA positive breast cancer (Std 90%)	87.1%	93.0%	70.5%	88.8%

Colon Cancer Measures

Measure	SHC Shea	SHC Shea 95% C.I.	AZ Accredited programs	CoC Accredited Programs
Adjuvant chemotherapy is considered or administered within 4 months of diagnosis for patients under the age of 80 with AJCC Stage III (lymph node positive) colon cancer (90%)	83.3%	104.4%	73.1%	93.1%
At least 12 regional lymph nodes are removed and pathologically examined for resected colon cancer (Std 85%)	97%	102.8%	89.1%	86.6%

Rectal Cancer Measure

Measure	SHC Shea	SHC Shea 95% C.I.	AZ Accredited programs	CoC Accredited Programs
Radiation therapy is considered or administered within 6 months of diagnosis for patients under the age of 80 with clinical or pathologic AJCC T4N0M0 or Stage III receiving surgical resection for rectal cancer (Std unspecified)	N/A Zero eligible cases	-	85.7%	89.6%

The 95% Confidence Interval (C.I.) is a statistical tool for interpreting comparison data. In simplest terms, it means that there is a 95% chance that the true average value is contained within the specified range. The Commission on Cancer specifies that the upper limit of the 95% C.I. of a facility's measure should meet or exceed either the published standard's expected percentage or the actual percentage of all CoC accredited programs, collectively.

**PRIMARY SITE TABULATION
SCOTTSDALE HEALTHCARE
SYSTEM 2012**

PRIMARY SITE	TOTAL	CLASS		SEX		AJCC STAGE						
		A	N/A	M	F	0	I	II	III	IV	UNK	N/A
ALL SITES	3298	2785	513	1556	1742	295	972	450	283	433	500	365
ORAL CAVITY	56	49	7	37	19	0	9	5	6	23	12	1
LIP	0	0	0	0	0	0	0	0	0	0	0	0
TONGUE	19	19	0	14	5	0	5	3	1	7	3	0
OROPHARYNX	6	5	1	4	2	0	0	0	2	2	2	0
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0	0	0
OTHER	31	25	6	19	12	0	4	2	3	14	7	1
DIGESTIVE SYSTEM	457	361	96	273	184	23	75	60	53	131	105	10
ESOPHAGUS	24	16	8	19	5	0	6	2	6	5	5	0
STOMACH	31	24	7	23	8	1	7	1	2	12	8	0
COLON	141	123	18	81	60	14	21	18	20	28	40	0
RECTUM	64	51	13	41	23	6	12	13	6	10	17	0
ANUS/ANAL CANAL	12	11	1	2	10	1	0	4	4	2	1	0
LIVER	30	23	7	19	11	0	9	1	4	5	8	3
PANCREAS	124	86	38	69	55	0	16	17	7	62	20	2
OTHER	31	27	4	19	12	1	4	4	4	7	6	5
RESPIRATORY SYSTEM	317	271	46	167	150	2	98	23	51	123	19	1
NASAL/SINUS	4	3	1	3	1	0	2	0	0	2	0	0
LARYNX	16	15	1	14	2	2	5	2	2	3	2	0
LUNG/BRONCHUS	292	249	43	146	146	0	90	21	48	118	15	0
OTHER	5	4	1	4	1	0	1	0	1	0	2	1
BLOOD & BONE MARROW	232	124	108	141	91	0	0	0	0	1	0	231
LEUKEMIA	126	74	52	75	51	0	0	0	0	1	0	125
MULTIPLE MYELOMA	57	35	22	38	19	0	0	0	0	0	0	57
OTHER	49	15	34	28	21	0	0	0	0	0	0	49
BONE	26	24	2	14	12	0	11	3	0	3	9	0
CONNECT/SOFT TISSUE	50	45	5	27	23	0	10	12	8	5	12	3
SKIN	172	150	22	97	75	40	52	20	10	14	35	1
MELANOMA	165	146	19	90	75	40	51	19	9	12	33	1
OTHER	7	4	3	7	0	0	1	1	1	2	2	0
BREAST	573	523	50	1	572	112	213	134	27	17	69	1
FEMALE GENITAL	212	188	24	0	212	2	74	5	36	22	72	1
CERVIX UTERI	23	22	1	0	23	0	6	1	3	7	6	0
CORPUS UTERI	127	119	8	0	127	1	61	3	12	6	44	0
OVARY	55	40	15	0	55	0	3	1	21	9	21	0
VULVA	6	6	0	0	6	1	4	0	0	0	1	0
OTHER	1	1	0	0	1	0	0	0	0	0	0	1

Scottsdale Healthcare Shea 2013 Cancer Program Annual Report

PRIMARY SITE	TOTAL	CLASS		SEX		AJCC STAGE						
		A	N/A	M	F	0	I	II	III	IV	UNK	N/A
MALE GENITAL	394	343	51	394	0	0	165	128	25	17	59	0
PROSTATE	381	333	48	381	0	0	162	127	23	17	52	0
TESTIS	13	10	3	13	0	0	3	1	2	0	7	0
OTHER	0	0	0	0	0	0	0	0	0	0	0	0
URINARY SYSTEM	315	276	39	232	83	116	107	28	15	19	30	0
BLADDER	198	163	35	151	47	113	40	20	6	8	11	0
KIDNEY/RENAL	113	109	4	79	34	2	67	8	7	10	19	0
OTHER	4	4	0	2	2	1	0	0	2	1	0	0
BRAIN & CNS	43	40	3	15	28	0	0	0	0	0	0	43
BRAIN (BENIGN)	3	3	0	3	0	0	0	0	0	0	0	3
BRAIN (MALIGNANT)	18	16	2	8	10	0	0	0	0	0	0	18
OTHER	22	21	1	4	18	0	0	0	0	0	0	22
ENDOCRINE	241	225	16	53	188	0	128	8	24	6	66	9
THYROID	230	219	11	48	182	0	128	7	24	5	66	0
OTHER	11	6	5	5	6	0	0	1	0	1	0	9
LYMPHATIC SYSTEM	129	100	29	72	57	0	29	24	20	48	8	0
HODGKIN'S DISEASE	15	11	4	5	10	0	2	10	2	1	0	0
NON-HODGKIN'S	114	89	25	67	47	0	27	14	18	47	8	0
UNKNOWN PRIMARY	60	49	11	29	31	0	0	0	0	0	1	59
OTHER/ILL-DEFINED	21	17	4	4	17	0	1	0	8	4	3	5

Number of cases excluded: 25

This report EXCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases

PRIMARY SITE TABULATION SCOTTSDALE HEALTHCARE SHEA 2012

PRIMARY SITE	TOTAL	CLASS		SEX				AJCC STAGE					N/A
		A	N/A	M	F	0	I	II	III	IV	UNK		
ALL SITES	2080	1726	354	1057	1023	225	634	310	164	230	318	199	
ORAL CAVITY	26	21	5	18	8	0	4	2	2	12	5	1	
LIP	0	0	0	0	0	0	0	0	0	0	0	0	
TONGUE	11	11	0	9	2	0	3	2	1	4	1	0	
OROPHARYNX	4	3	1	3	1	0	0	0	1	1	2	0	
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0	0	0	

Scottsdale Healthcare Shea 2013 Cancer Program Annual Report

PRIMARY SITE	TOTAL	CLASS		SEX				AJCC STAGE				
		A	N/A	M	F	0	I	II	III	IV	UNK	N/A
OTHER	11	7	4	6	5	0	1	0	0	7	2	1
DIGESTIVE SYSTEM	272	198	74	162	110	10	44	38	35	72	69	4
ESOPHAGUS	10	5	5	9	1	0	3	2	3	1	1	0
STOMACH	18	12	6	14	4	1	4	1	2	6	4	0
COLON	79	67	12	46	33	5	13	9	11	14	27	0
RECTUM	44	32	12	27	17	3	9	7	5	8	12	0
ANUS/ANAL CANAL	8	7	1	0	8	0	0	3	3	2	0	0
LIVER	14	10	4	9	5	0	4	0	2	3	5	0
PANCREAS	82	50	32	46	36	0	9	13	7	34	17	2
OTHER	17	15	2	11	6	1	2	3	2	4	3	2
RESPIRATORY SYSTEM	148	121	27	84	64	2	44	15	19	56	11	1
NASAL/SINUS	0	0	0	0	0	0	0	0	0	0	0	0
LARYNX	8	7	1	8	0	2	0	1	2	2	1	0
LUNG/BRONCHUS	137	112	25	74	63	0	43	14	17	54	9	0
OTHER	3	2	1	2	1	0	1	0	0	0	1	1
BLOOD & BONE MARROW	155	84	71	93	62	0	0	0	0	1	0	154
LEUKEMIA	83	48	35	48	35	0	0	0	0	1	0	82
MULTIPLE MYELOMA	47	27	20	30	17	0	0	0	0	0	0	47
OTHER	25	9	16	15	10	0	0	0	0	0	0	25
BONE	23	22	1	13	10	0	9	3	0	3	8	0
CONNECT/SOFT TISSUE	33	30	3	16	17	0	6	7	6	2	10	2
SKIN	97	81	16	52	45	25	27	11	4	8	22	0
MELANOMA	93	79	14	48	45	25	26	10	4	7	21	0
OTHER	4	2	2	4	0	0	1	1	0	1	1	0
BREAST	397	366	31	0	397	85	151	90	18	7	45	1
FEMALE GENITAL	62	44	18	0	62	2	15	1	10	8	26	0
CERVIX UTERI	10	9	1	0	10	0	2	1	1	3	3	0
CORPUS UTERI	33	29	4	0	33	1	13	0	2	3	14	0
OVARY	18	5	13	0	18	0	0	0	7	2	9	0
VULVA	1	1	0	0	1	1	0	0	0	0	0	0
OTHER	0	0	0	0	0	0	0	0	0	0	0	0
MALE GENITAL	326	293	33	326	0	0	140	103	23	13	47	0
PROSTATE	313	283	30	313	0	0	137	102	21	13	40	0
TESTIS	13	10	3	13	0	0	3	1	2	0	7	0
OTHER	0	0	0	0	0	0	0	0	0	0	0	0
URINARY SYSTEM	260	226	34	193	67	101	86	24	11	16	22	0
BLADDER	165	135	30	126	39	98	33	17	4	7	6	0
KIDNEY/RENAL	92	88	4	65	27	2	53	7	6	8	16	0
OTHER	3	3	0	2	1	1	0	0	1	1	0	0

Scottsdale Healthcare Shea 2013 Cancer Program Annual Report

PRIMARY SITE	TOTAL	CLASS		SEX		0	I	AJCC STAGE				
		A	N/A	M	F			II	III	IV	UNK	N/A
BRAIN & CNS	6	5	1	1	5	0	0	0	0	0	0	6
BRAIN (BENIGN)	0	0	0	0	0	0	0	0	0	0	0	0
BRAIN (MALIGNANT)	3	3	0	1	2	0	0	0	0	0	0	3
OTHER	3	2	1	0	3	0	0	0	0	0	0	3
ENDOCRINE	178	165	13	43	135	0	94	7	23	1	45	8
THYROID	169	161	8	38	131	0	94	6	23	1	45	0
OTHER	9	4	5	5	4	0	0	1	0	0	0	8
LYMPHATIC SYSTEM	68	49	19	44	24	0	13	9	11	29	6	0
HODGKIN'S DISEASE	9	6	3	3	6	0	0	6	2	1	0	0
NON-HODGKIN'S	59	43	16	41	18	0	13	3	9	28	6	0
UNKNOWN PRIMARY	20	14	6	8	12	0	0	0	0	0	1	19
OTHER/ILL-DEFINED	9	7	2	4	5	0	1	0	2	2	1	3

Number of cases excluded: 5

This report EXCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases

**PRIMARY SITE TABULATION
SCOTTSDALE HEALTHCARE
OSBORN 2012**

PRIMARY SITE	TOTAL	CLASS		SEX		AJCC STAGE						
		A	N/A	M	F	0	I	II	III	IV	UNK	N/A
ALL SITES	758	646	112	319	439	51	187	91	63	138	91	137
ORAL CAVITY	23	21	2	12	11	0	3	1	3	11	5	0
LIP	0	0	0	0	0	0	0	0	0	0	0	0
TONGUE	6	6	0	3	3	0	2	0	0	3	1	0
OROPHARYNX	2	2	0	1	1	0	0	0	1	1	0	0
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0	0	0
OTHER	15	13	2	8	7	0	1	1	2	7	4	0
DIGESTIVE SYSTEM	130	117	13	78	52	10	19	17	12	42	25	5
ESOPHAGUS	12	10	2	8	4	0	3	0	2	3	4	0
STOMACH	9	8	1	7	2	0	2	0	0	4	3	0
COLON	43	40	3	24	19	8	4	7	5	10	9	0
RECTUM	13	13	0	9	4	1	1	5	0	1	5	0
ANUS/ANAL CANAL	2	2	0	0	2	1	0	0	1	0	0	0
LIVER	12	11	1	9	3	0	3	1	2	1	2	3
PANCREAS	32	27	5	17	15	0	6	3	0	21	2	0
OTHER	7	6	1	4	3	0	0	1	2	2	0	2
PRIMARY SITE	TOTAL	CLASS		SEX		AJCC STAGE						
		A	N/A	M	F	0	I	II	III	IV	UNK	N/A

Scottsdale Healthcare Shea 2013 Cancer Program Annual Report

RESPIRATORY SYSTEM	124	112	12	61	63	0	40	5	22	50	7	0
NASAL/SINUS	2	2	0	1	1	0	1	0	0	1	0	0
LARYNX	6	6	0	4	2	0	3	1	0	1	1	0
LUNG/BRONCHUS	115	103	12	55	60	0	36	4	22	48	5	0
OTHER	1	1	0	1	0	0	0	0	0	0	1	0
BLOOD & BONE												
MARROW	66	32	34	39	27	0	0	0	0	0	0	66
LEUKEMIA	37	21	16	22	15	0	0	0	0	0	0	37
MULTIPLE MYELOMA	9	7	2	7	2	0	0	0	0	0	0	9
OTHER	20	4	16	10	10	0	0	0	0	0	0	20
BONE	1	1	0	1	0	0	1	0	0	0	0	0
CONNECT/SOFT TISSUE	10	8	2	6	4	0	1	3	2	2	1	1
SKIN	56	52	4	40	16	13	20	8	4	3	7	1
MELANOMA	53	50	3	37	16	13	20	8	3	2	6	1
OTHER	3	2	1	3	0	0	0	0	1	1	1	0
BREAST	147	136	11	0	147	24	60	38	8	3	14	0
FEMALE GENITAL	13	12	1	0	13	0	2	0	0	5	5	1
CERVIX UTERI	3	3	0	0	3	0	1	0	0	1	1	0
CORPUS UTERI	3	3	0	0	3	0	1	0	0	0	2	0
OVARY	6	5	1	0	6	0	0	0	0	4	2	0
VULVA	0	0	0	0	0	0	0	0	0	0	0	0
OTHER	1	1	0	0	1	0	0	0	0	0	0	1
MALE GENITAL	21	10	11	21	0	0	3	7	0	4	7	0
PROSTATE	21	10	11	21	0	0	3	7	0	4	7	0
TESTIS	0	0	0	0	0	0	0	0	0	0	0	0
OTHER	0	0	0	0	0	0	0	0	0	0	0	0
URINARY SYSTEM	19	16	3	11	8	4	7	1	1	1	5	0
BLADDER	10	7	3	6	4	4	0	1	0	1	4	0
KIDNEY/RENAL	9	9	0	5	4	0	7	0	1	0	1	0
OTHER	0	0	0	0	0	0	0	0	0	0	0	0
BRAIN & CNS	36	34	2	13	23	0	0	0	0	0	0	36
BRAIN (BENIGN)	3	3	0	3	0	0	0	0	0	0	0	3
BRAIN (MALIGNANT)	15	13	2	7	8	0	0	0	0	0	0	15
OTHER	18	18	0	3	15	0	0	0	0	0	0	18
ENDOCRINE	33	30	3	4	29	0	16	0	1	3	13	0
THYROID	32	29	3	4	28	0	16	0	1	2	13	0
OTHER	1	1	0	0	1	0	0	0	0	1	0	0
PRIMARY SITE	TOTAL	CLASS		SEX				AJCC				
		A	N/A	M	F	0	I	II	III	IV	UNK	N/A

Scottsdale Healthcare Shea 2013 Cancer Program Annual Report

LYMPHATIC SYSTEM	49	41	8	21	28	0	15	11	8	13	2	0
HODGKIN'S DISEASE	4	4	0	2	2	0	2	2	0	0	0	0
NON-HODGKIN'S	45	37	8	19	26	0	13	9	8	13	2	0
UNKNOWN PRIMARY	27	22	5	12	15	0	0	0	0	0	0	27
OTHER/ILL-DEFINED	3	2	1	0	3	0	0	0	2	1	0	0

Number of cases excluded: 1

This report EXCLUDES CA in-situ cervix cases, squamous and basal cell skin cases, and intraepithelial neoplasia cases

**PRIMARY SITE TABULATION
SCOTTSDALE HEALTHCARE
THOMPSON PEAK 2012**

PRIMARY SITE	TOTAL	CLASS		SEX				AJCC STAGE					N/A
		A	N/A	M	F	0	I	II	III	IV	UNK		
ALL SITES	460	413	47	180	280	19	151	50	55	65	91	29	
ORAL CAVITY	7	7	0	7	0	0	2	2	1	0	2	0	
LIP	0	0	0	0	0	0	0	0	0	0	0	0	
TONGUE	2	2	0	2	0	0	0	1	0	0	1	0	
OROPHARYNX	0	0	0	0	0	0	0	0	0	0	0	0	
HYPOPHARYNX	0	0	0	0	0	0	0	0	0	0	0	0	
OTHER	5	5	0	5	0	0	2	1	1	0	1	0	
DIGESTIVE SYSTEM	55	46	9	33	22	3	12	5	6	17	11	1	
ESOPHAGUS	2	1	1	2	0	0	0	0	1	1	0	0	
STOMACH	4	4	0	2	2	0	1	0	0	2	1	0	
COLON	19	16	3	11	8	1	4	2	4	4	4	0	
RECTUM	7	6	1	5	2	2	2	1	1	1	0	0	
ANUS/ANAL CANAL	2	2	0	2	0	0	0	1	0	0	1	0	
LIVER	4	2	2	1	3	0	2	0	0	1	1	0	
PANCREAS	10	9	1	6	4	0	1	1	0	7	1	0	
OTHER	7	6	1	4	3	0	2	0	0	1	3	1	
RESPIRATORY SYSTEM	44	37	7	21	23	0	14	3	9	17	1	0	
NASAL/SINUS	2	1	1	2	0	0	1	0	0	1	0	0	
LARYNX	2	2	0	2	0	0	2	0	0	0	0	0	
LUNG/BRONCHUS	39	33	6	16	23	0	11	3	8	16	1	0	
OTHER	1	1	0	1	0	0	0	0	1	0	0	0	
BLOOD & BONE MARROW	11	8	3	9	2	0	0	0	0	0	0	11	
PRIMARY SITE	TOTAL	CLASS		SEX				AJCC STAGE					N/A
		A	N/A	M	F	0	I	II	III	IV	UNK		
LEUKEMIA	6	5	1	5	1	0	0	0	0	0	0	6	
MULTIPLE MYELOMA	1	1	0	1	0	0	0	0	0	0	0	1	

Scottsdale Healthcare Shea 2013 Cancer Program Annual Report

OTHER	4	2	2	3	1	0	0	0	0	0	0	4
BONE	2	1	1	0	2	0	1	0	0	0	1	0
CONNECT/SOFT TISSUE	7	7	0	5	2	0	3	2	0	1	1	0
SKIN	19	17	2	5	14	2	5	1	2	3	6	0
MELANOMA	19	17	2	5	14	2	5	1	2	3	6	0
OTHER	0	0	0	0	0	0	0	0	0	0	0	0
BREAST	29	21	8	1	28	3	2	6	1	7	10	0
FEMALE GENITAL	137	132	5	0	137	0	57	4	26	9	41	0
CERVIX UTERI	10	10	0	0	10	0	3	0	2	3	2	0
CORPUS UTERI	91	87	4	0	91	0	47	3	10	3	28	0
OVARY	31	30	1	0	31	0	3	1	14	3	10	0
VULVA	5	5	0	0	5	0	4	0	0	0	1	0
OTHER	0	0	0	0	0	0	0	0	0	0	0	0
MALE GENITAL	48	41	7	48	0	0	22	19	2	0	5	0
PROSTATE	48	41	7	48	0	0	22	19	2	0	5	0
TESTIS	0	0	0	0	0	0	0	0	0	0	0	0
OTHER	0	0	0	0	0	0	0	0	0	0	0	0
URINARY SYSTEM	36	34	2	28	8	11	14	3	3	2	3	0
BLADDER	23	21	2	19	4	11	7	2	2	0	1	0
KIDNEY/RENAL	12	12	0	9	3	0	7	1	0	2	2	0
OTHER	1	1	0	0	1	0	0	0	1	0	0	0
BRAIN & CNS	1	1	0	1	0	0	0	0	0	0	0	1
BRAIN (BENIGN)	0	0	0	0	0	0	0	0	0	0	0	0
BRAIN (MALIGNANT)	0	0	0	0	0	0	0	0	0	0	0	0
OTHER	1	1	0	1	0	0	0	0	0	0	0	1
ENDOCRINE	30	30	0	6	24	0	18	1	0	2	8	1
THYROID	29	29	0	6	23	0	18	1	0	2	8	0
OTHER	1	1	0	0	1	0	0	0	0	0	0	1
LYMPHATIC SYSTEM	12	10	2	7	5	0	1	4	1	6	0	0
HODGKIN'S DISEASE	2	1	1	0	2	0	0	2	0	0	0	0
NON-HODGKIN'S	10	9	1	7	3	0	1	2	1	6	0	0
UNKNOWN PRIMARY	13	13	0	9	4	0	0	0	0	0	0	13
OTHER/ILL-DEFINED	9	8	1	0	9	0	0	0	4	1	2	2